Medical News

[ Interim Results Of Neuralstem ALS Stem Cell Trial ]

Interim Results Of Neuralstem ALS Stem Cell Trial

Neuralstem, Inc. (NYSE Amex: CUR) announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease ) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cell. "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients" reports that one patient has shown improvement in his clinical status, even though researchers caution that the study was not designed to show efficacy. Additionally, there was no evidence of accelerated disease progression due to the intervention in any of the 12 patients, who were followed from 6-18 months after they were transplanted with the cells. All of the patients, who received transplants in the lumbar (lower back) region, tolerated the treatment without any long-term complications related to either the surgery or the cells.

Key Mechanism Behind Lymphoma Targeted By New Compound

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings was announced at the AACR Annual Meeting 2012. "It's an exciting time to be involved in lymphoma treatment and research, " says study author Mitchell Smith, M.D., Ph.D., director of Lymphoma Service at Fox Chase. "There's a new understanding of the disease, and new drugs to treat it. I am optimistic that over the next couple of years treatments will continue to get even better and less toxic." During the study, Smith and his colleagues investigated a compound known as TL32711 (Birinapant), developed by TetraLogic Pharmaceuticals in Malvern, Pennsylvania. The compound works by blocking the process cells used to avoid death, he explains - in other words, it inhibits the process that inhibits cell death.

First Targeted Nanomedicine To Enter Human Clinical Studies

A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors. BIND-014 is the first targeted and programmed nanomedicine to enter human clinical studies. The study has been electronically published in Science Translational Medicine. In the study, the researchers demonstrate BIND-014's ability to effectively target a receptor expressed in tumors to achieve high tumor drug concentrations, as well as show remarkable efficacy, safety and pharmacological properties compared to the parent chemotherapeutic drug, docetaxel ( Taxotere ).

Researchers Prepare Clinical Trial That Will Use Fat-Enclosed Nanoparticles To Accurately Irradiate Brain Tumors

For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. But, although the targeting technology has been refined, beams of radiation still must pass through healthy brain tissue to reach the tumor, and patients can only tolerate small amounts before developing serious side effects. A group of researchers at The University of Texas Health Science Center at San Antonio have developed a way to deliver nanoparticle radiation directly to the brain tumor and keep it there. The method doses the tumor itself with much higher levels of radiation - 20 to 30 times the current dose of radiation therapy to patients - but spares a much greater area of brain tissue. The study, published in the journal Neuro-Oncology, has been successful enough in laboratory experiments that they're preparing to start a clinical trial at the Cancer Therapy & Research Center, said Andrew Brenner, M.

Clinicians May Be Mislead Over Effectiveness Of Newer Anti-Psychotic Drugs

A study in this week's PLoS Medicine suggests that the apparent clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses (second-generation anti-psychotic drugs) may be enhanced by the selective reporting of trials of these drugs in medical journals - a phenomenon called publication bias. This finding is important as the results of published trials influence clinicians' decisions to prescribe drugs. The authors, led by Erick Turner from Oregon Health & Science University in Portland, USA, say: "Selective reporting of research results undermines the integrity of the evidence base, which ultimately deprives clinicians of accurate data for prescribing decisions." The authors reached these conclusions by reviewing 24 FDA-registered premarketing trials for eight second-generation antipsychotics - aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection, and ziprasidone - and then comparing these trials with the results conveyed in subsequent articles in medical journals.

Medical News © Nanda
Designer Damodar